Pacific Biosciences of California (STU:P09) Total Liabilities : €939.2 Mil (As of Mar. 2024)

View and export this data going back to 2015. Start your Free Trial

What is Pacific Biosciences of California Total Liabilities?

Pacific Biosciences of California's Total Liabilities for the quarter that ended in Mar. 2024 was €939.2 Mil.

Pacific Biosciences of California's quarterly Total Liabilities declined from Sep. 2023 (€1,063.13 Mil) to Dec. 2023 (€958.00 Mil) and declined from Dec. 2023 (€958.00 Mil) to Mar. 2024 (€939.23 Mil).

Pacific Biosciences of California's annual Total Liabilities increased from Dec. 2021 (€1,076.15 Mil) to Dec. 2022 (€1,136.75 Mil) but then declined from Dec. 2022 (€1,136.75 Mil) to Dec. 2023 (€958.00 Mil).

Pacific Biosciences of California Total Liabilities Historical Data

The historical data trend for Pacific Biosciences of California's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Pacific Biosciences of California Total Liabilities Chart

Pacific Biosciences of California Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Liabilities

Get a 7-Day Free Trial

83.76

64.52

1,076.15

1,136.75

958.00

Pacific Biosciences of California Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Total Liabilities	Get a 7-Day Free Trial															1,124.82	1,112.80	1,063.13	958.00	939.23

Pacific Biosciences of California Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Pacific Biosciences of California's Total Liabilities for the fiscal year that ended in Dec. 2023 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	87.142	+	(847.17	+	18.615
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	5.071	+	0)
	=	958.0

Total Liabilities	=	Total Assets (A: Dec. 2023 )	-	Total Equity (A: Dec. 2023 )
	=	1601.094	-	643.096
	=	958.0

Pacific Biosciences of California's Total Liabilities for the quarter that ended in Mar. 2024 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	67.115	+	(847.866	+	18.613
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	5.637	+	0)
	=	939.2

Total Liabilities	=	Total Assets (Q: Mar. 2024 )	-	Total Equity (Q: Mar. 2024 )
	=	1536.326	-	597.096
	=	939.2

Pacific Biosciences of California Total Liabilities Related Terms

Thank you for viewing the detailed overview of Pacific Biosciences of California's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Pacific Biosciences of California (STU:P09) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Pacific Biosciences of California Inc (STU:P09) » Definitions » Total Liabilities

Comparable Companies

Traded in Other Exchanges

PACB:USA

Address

1305 O’Brien Drive, Menlo Park, CA, USA, 94025

Website

https://www.pacb.com

Pacific Biosciences of California Inc is a biotechnology company focused on the design, development, and commercialization of tools for biological research. The company develops sequencing systems to assist in resolving genetically complex problems. Its sequencing systems provide access to a wide range of applications and are designed for expandable improvements to performance capability. The majority of the company's revenue is derived from North America, followed by Asia and Europe.

Pacific Biosciences of California (STU:P09) Headlines

No Headlines